ESR1 and neoplasm: Compelling evidence suggests that breast cancer growth in at least some ER+ and HER2-overexpressing tumours is regulated by bi-directional crosstalk between ER and HER2 signalling pathways that can drive the development of resistance to endocrine therapy (Arpino et al. 2008, Goutsouliak et al. 2020) (Fig. 2).